Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Immunocore Holdings plc or Aurinia Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Immunocore Holdings plc and Aurinia Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Immunocore Holdings plc and Aurinia Pharmaceuticals Inc.
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Latest Biotechnology and Immunocore Holdings plc, Aurinia Pharmaceuticals Inc. Stock News
As of November 25, 2025, Immunocore Holdings plc had a $2.0 billion market capitalization, compared to the Biotechnology median of $209.4 million. Immunocore Holdings plc’s stock is up 36% in 2025, up 3.8% in the previous five trading days and up 19.34% in the past year.
Currently, Immunocore Holdings plc does not have a price-earnings ratio. Immunocore Holdings plc’s trailing 12-month revenue is $379.6 million with a -7.7% net profit margin. Year-over-year quarterly sales growth most recently was 29.3%. There are no analysts providing consensus earnings estimates for the current fiscal year. Immunocore Holdings plc does not currently pay a dividend.
As of November 25, 2025, Aurinia Pharmaceuticals Inc. had a $2.1 billion market cap, putting it in the 57th percentile of all stocks. Aurinia Pharmaceuticals Inc.’s stock is up 82.4% in 2025, up 7.8% in the previous five trading days and up 85.63% in the past year.
Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 29.6. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $265.8 million with a 29.3% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $0.782 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.
How We Compare Immunocore Holdings plc and Aurinia Pharmaceuticals Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Immunocore Holdings plc and Aurinia Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions